Pulmonary Arterial Hypertension (PAH) Drugs Market Report

Global and Region Pulmonary Arterial Hypertension (PAH) Drugs Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Jul 31, 2022
  • PAGES：201
  • REPORT CODE：GMM937114
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The report details the trend, potential and market size of Pulmonary Arterial Hypertension (PAH) Drugs market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Pulmonary Arterial Hypertension (PAH) Drugsmarket, defines the market attractiveness level of Pulmonary Arterial Hypertension (PAH) Drugs market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Pulmonary Arterial Hypertension (PAH) Drugs industry, describes the types of Pulmonary Arterial Hypertension (PAH) Drugs market, the applications of major players and the market size, and deeply analyzes the current situation of the global Pulmonary Arterial Hypertension (PAH) Drugs market and the development prospects and opportunities of Pulmonary Arterial Hypertension (PAH) Drugs industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Pulmonary Arterial Hypertension (PAH) Drugs market in Chapter 13.

    By Player:

    • Novartis

    • Reata Pharmaceuticals

    • Eiger BioPharmaceuticals

    • United Therapeutics

    • Northern Therapeutics

    • AstraZeneca

    • Arena Pharmaceuticals

    • Pfizer

    • Berlin Cures

    • Daiichi Sankyo

    • Aires Pharmaceuticals

    • Actelion Pharmaceuticals

    • Bayer Healthcare

    • Glaxosmithkline

    • Merck

    By Type:

    • Inhalation

    • Injectables

    • Oral Administration

    By End-User:

    • Hospitals

    • Clinics

    • Other

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Pulmonary Arterial Hypertension (PAH) Drugs Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Pulmonary Arterial Hypertension (PAH) Drugs Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Pulmonary Arterial Hypertension (PAH) Drugs Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Pulmonary Arterial Hypertension (PAH) Drugs Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Pulmonary Arterial Hypertension (PAH) Drugs Market Analysis and Outlook to 2022

    • 7.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Consumption (2017-2022)

    • 7.2 United States Pulmonary Arterial Hypertension (PAH) Drugs Consumption (2017-2022)

    • 7.3 Europe Pulmonary Arterial Hypertension (PAH) Drugs Consumption (2017-2022)

    • 7.4 China Pulmonary Arterial Hypertension (PAH) Drugs Consumption (2017-2022)

    • 7.5 Japan Pulmonary Arterial Hypertension (PAH) Drugs Consumption (2017-2022)

    • 7.6 India Pulmonary Arterial Hypertension (PAH) Drugs Consumption (2017-2022)

    • 7.7 South Korea Pulmonary Arterial Hypertension (PAH) Drugs Consumption (2017-2022)

    8 Region and Country-wise Pulmonary Arterial Hypertension (PAH) Drugs Market Analysis and Outlook to 2028

    • 8.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast (2022-2028)

    • 8.2 United States Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast (2022-2028)

    • 8.3 Europe Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast (2022-2028)

    • 8.4 China Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast (2022-2028)

    • 8.5 Japan Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast (2022-2028)

    • 8.6 India Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast (2022-2028)

    • 8.7 South Korea Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast (2022-2028)

    9 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Outlook by Types and Applications to 2022

    • 9.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Inhalation Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Injectables Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Oral Administration Consumption and Growth Rate (2017-2022)

    • 9.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospitals Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Clinics Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Other Consumption and Growth Rate (2017-2022)

    10 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Outlook by Types and Applications to 2028

    • 10.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global Inhalation Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global Injectables Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global Oral Administration Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Hospitals Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Clinics Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.3 Global Other Consumption Forecast and Growth Rate (2022-2028)

    11 Global Pulmonary Arterial Hypertension (PAH) Drugs Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Pulmonary Arterial Hypertension (PAH) Drugs Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Competitive Analysis

    • 14.1 Novartis

      • 14.1.1 Novartis Company Details

      • 14.1.2 Novartis Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 Novartis Pulmonary Arterial Hypertension (PAH) Drugs Product and Service

    • 14.2 Reata Pharmaceuticals

      • 14.2.1 Reata Pharmaceuticals Company Details

      • 14.2.2 Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product and Service

    • 14.3 Eiger BioPharmaceuticals

      • 14.3.1 Eiger BioPharmaceuticals Company Details

      • 14.3.2 Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product and Service

    • 14.4 United Therapeutics

      • 14.4.1 United Therapeutics Company Details

      • 14.4.2 United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Product and Service

    • 14.5 Northern Therapeutics

      • 14.5.1 Northern Therapeutics Company Details

      • 14.5.2 Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Product and Service

    • 14.6 AstraZeneca

      • 14.6.1 AstraZeneca Company Details

      • 14.6.2 AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Product and Service

    • 14.7 Arena Pharmaceuticals

      • 14.7.1 Arena Pharmaceuticals Company Details

      • 14.7.2 Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product and Service

    • 14.8 Pfizer

      • 14.8.1 Pfizer Company Details

      • 14.8.2 Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.8.3 Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Product and Service

    • 14.9 Berlin Cures

      • 14.9.1 Berlin Cures Company Details

      • 14.9.2 Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.9.3 Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Product and Service

    • 14.10 Daiichi Sankyo

      • 14.10.1 Daiichi Sankyo Company Details

      • 14.10.2 Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.10.3 Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Product and Service

    • 14.11 Aires Pharmaceuticals

      • 14.11.1 Aires Pharmaceuticals Company Details

      • 14.11.2 Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.11.3 Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product and Service

    • 14.12 Actelion Pharmaceuticals

      • 14.12.1 Actelion Pharmaceuticals Company Details

      • 14.12.2 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.12.3 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product and Service

    • 14.13 Bayer Healthcare

      • 14.13.1 Bayer Healthcare Company Details

      • 14.13.2 Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.13.3 Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Product and Service

    • 14.14 Glaxosmithkline

      • 14.14.1 Glaxosmithkline Company Details

      • 14.14.2 Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.14.3 Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Product and Service

    • 14.15 Merck

      • 14.15.1 Merck Company Details

      • 14.15.2 Merck Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.15.3 Merck Pulmonary Arterial Hypertension (PAH) Drugs Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Pulmonary Arterial Hypertension (PAH) Drugs

    • Figure Pulmonary Arterial Hypertension (PAH) Drugs Picture

    • Table Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Pulmonary Arterial Hypertension (PAH) Drugs Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Pulmonary Arterial Hypertension (PAH) Drugs Consumption by Country (2017-2022)

    • Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate (2017-2022)

    • Table Europe Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate (2017-2022)

    • Figure China Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate (2017-2022)

    • Figure Japan Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate (2017-2022)

    • Figure India Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate (2017-2022)

    • Figure South Korea Pulmonary Arterial Hypertension (PAH) Drugs Consumption and Growth Rate (2017-2022)

    • Figure Global Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast by Country (2022-2028)

    • Figure United States Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Pulmonary Arterial Hypertension (PAH) Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Inhalation Consumption and Growth Rate (2017-2022)

    • Figure Global Injectables Consumption and Growth Rate (2017-2022)

    • Figure Global Oral Administration Consumption and Growth Rate (2017-2022)

    • Figure Global Hospitals Consumption and Growth Rate (2017-2022)

    • Figure Global Clinics Consumption and Growth Rate (2017-2022)

    • Figure Global Other Consumption and Growth Rate (2017-2022)

    • Figure Global Inhalation Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Injectables Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Oral Administration Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospitals Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Clinics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Other Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Pulmonary Arterial Hypertension (PAH) Drugs Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Pulmonary Arterial Hypertension (PAH) Drugs Export by Region (Top 5 Countries) (2017-2028)

    • Table Novartis (Foundation Year, Company Profile and etc.)

    • Table Novartis Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Novartis Pulmonary Arterial Hypertension (PAH) Drugs Product and Service

    • Table Reata Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product and Service

    • Table Eiger BioPharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product and Service

    • Table United Therapeutics (Foundation Year, Company Profile and etc.)

    • Table United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Product and Service

    • Table Northern Therapeutics (Foundation Year, Company Profile and etc.)

    • Table Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Product and Service

    • Table AstraZeneca (Foundation Year, Company Profile and etc.)

    • Table AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Product and Service

    • Table Arena Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product and Service

    • Table Pfizer (Foundation Year, Company Profile and etc.)

    • Table Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Product and Service

    • Table Berlin Cures (Foundation Year, Company Profile and etc.)

    • Table Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Product and Service

    • Table Daiichi Sankyo (Foundation Year, Company Profile and etc.)

    • Table Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Product and Service

    • Table Aires Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product and Service

    • Table Actelion Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product and Service

    • Table Bayer Healthcare (Foundation Year, Company Profile and etc.)

    • Table Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Product and Service

    • Table Glaxosmithkline (Foundation Year, Company Profile and etc.)

    • Table Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Product and Service

    • Table Merck (Foundation Year, Company Profile and etc.)

    • Table Merck Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Merck Pulmonary Arterial Hypertension (PAH) Drugs Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US